JP2022532865A5 - - Google Patents
Info
- Publication number
- JP2022532865A5 JP2022532865A5 JP2021564704A JP2021564704A JP2022532865A5 JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5 JP 2021564704 A JP2021564704 A JP 2021564704A JP 2021564704 A JP2021564704 A JP 2021564704A JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition according
- grade
- administered
- neurotoxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013168A JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843190P | 2019-05-03 | 2019-05-03 | |
| US62/843,190 | 2019-05-03 | ||
| US201962855828P | 2019-05-31 | 2019-05-31 | |
| US62/855,828 | 2019-05-31 | ||
| US201962868262P | 2019-06-28 | 2019-06-28 | |
| US62/868,262 | 2019-06-28 | ||
| US201962931669P | 2019-11-06 | 2019-11-06 | |
| US62/931,669 | 2019-11-06 | ||
| US201962944903P | 2019-12-06 | 2019-12-06 | |
| US62/944,903 | 2019-12-06 | ||
| PCT/US2020/031231 WO2020227177A1 (en) | 2019-05-03 | 2020-05-03 | Methods of administering chimeric antigen receptor immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Division JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532865A JP2022532865A (ja) | 2022-07-20 |
| JP2022532865A5 true JP2022532865A5 (cg-RX-API-DMAC7.html) | 2023-05-15 |
Family
ID=73050885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564704A Pending JP2022532865A (ja) | 2019-05-03 | 2020-05-03 | キメラ抗原受容体免疫療法の投与方法 |
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Country Status (13)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206346A (zh) * | 2019-05-03 | 2022-03-18 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| AU2021391623A1 (en) * | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| CA3203531A1 (en) | 2020-12-30 | 2022-07-07 | Simon Olivares | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CN117295507A (zh) * | 2021-05-14 | 2023-12-26 | 凯德药业股份有限公司 | 嵌合抗原受体t细胞疗法 |
| CN113406334A (zh) * | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型 |
| KR20240027077A (ko) * | 2021-07-30 | 2024-02-29 | 카이트 파마 인코포레이티드 | 세포 요법-유도 독성의 모니터링 및 관리 |
| CN113786490A (zh) * | 2021-09-14 | 2021-12-14 | 华中科技大学同济医学院附属协和医院 | 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用 |
| CN117357637A (zh) * | 2022-06-30 | 2024-01-09 | 上海优卡迪生物医药科技有限公司 | 一种治疗肿瘤的联合用药物组合物及其用途 |
| WO2026092543A1 (en) * | 2024-10-29 | 2026-05-07 | Shenzhen Genocury Biotech Co., Ltd | Methods and compositions of prophylactic therapy for preventing crs |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| AU687763B2 (en) | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| EP3018145B1 (en) * | 2010-10-27 | 2018-04-04 | Amgen Research (Munich) GmbH | Means and methods for treating dlbcl |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| EP3484455A2 (en) * | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| BR102018008260A2 (pt) * | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| IL327498A (en) * | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111757744A (zh) * | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| EP3697500A1 (en) * | 2017-10-18 | 2020-08-26 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| CN114206346A (zh) * | 2019-05-03 | 2022-03-18 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
-
2020
- 2020-05-03 CN CN202080043985.XA patent/CN114206346A/zh active Pending
- 2020-05-03 KR KR1020217039585A patent/KR20220005075A/ko not_active Ceased
- 2020-05-03 JP JP2021564704A patent/JP2022532865A/ja active Pending
- 2020-05-03 TW TW109114736A patent/TW202108150A/zh unknown
- 2020-05-03 CN CN202410645821.4A patent/CN118662516A/zh active Pending
- 2020-05-03 CN CN202410645866.1A patent/CN118593691A/zh active Pending
- 2020-05-03 BR BR112021021996A patent/BR112021021996A2/pt unknown
- 2020-05-03 US US16/865,369 patent/US20200384027A1/en not_active Abandoned
- 2020-05-03 EP EP23186520.5A patent/EP4249075A3/en active Pending
- 2020-05-03 WO PCT/US2020/031231 patent/WO2020227177A1/en not_active Ceased
- 2020-05-03 SG SG11202112123RA patent/SG11202112123RA/en unknown
- 2020-05-03 MX MX2021013394A patent/MX2021013394A/es unknown
- 2020-05-03 KR KR1020267016691A patent/KR20260091586A/ko active Pending
- 2020-05-03 EP EP20801592.5A patent/EP3962490A4/en not_active Withdrawn
- 2020-05-03 CA CA3138707A patent/CA3138707A1/en active Pending
- 2020-05-03 AU AU2020267378A patent/AU2020267378B2/en active Active
-
2021
- 2021-10-24 IL IL287533A patent/IL287533A/en unknown
-
2023
- 2023-02-10 US US18/167,725 patent/US20230270785A1/en active Pending
-
2025
- 2025-01-29 JP JP2025013168A patent/JP2025069275A/ja active Pending
- 2025-04-30 AU AU2025203054A patent/AU2025203054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156736A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | PD-1/PD-L1 inhibitors in cervical cancer | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Goldstein et al. | Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. | |
| Peng et al. | Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer | |
| Li et al. | IDO1: an important immunotherapy target in cancer treatment | |
| JP2022078265A5 (cg-RX-API-DMAC7.html) | ||
| JP2019516748A5 (cg-RX-API-DMAC7.html) | ||
| Behnamfar et al. | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia | |
| JP2014533279A5 (cg-RX-API-DMAC7.html) | ||
| Xiao et al. | Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer | |
| JP2008515890A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522851A5 (cg-RX-API-DMAC7.html) | ||
| Lyons et al. | Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia | |
| JP2023521227A5 (cg-RX-API-DMAC7.html) | ||
| JP2022527373A5 (cg-RX-API-DMAC7.html) | ||
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| JPWO2020250915A5 (cg-RX-API-DMAC7.html) | ||
| Maggiore et al. | Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients? | |
| Spies et al. | Prednisone chronotherapy | |
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| Nastoupil et al. | CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received≥ 1 line of systemic therapy | |
| Zhang et al. | Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma | |
| Gao et al. | Lb0009 allogenic cd19 car nk cell therapy in refractory systemic lupus erythematosus-a case series study | |
| Diéras et al. | Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies |